ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

HDM2020

A development code. Also written as “HDM2020 (FGFR2b-ADC)”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Huadong Medicine.

Furthest: phase 1, since Jul 18, 20252 company-led studies, 2 open or runningNext primary completion: Jan 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Huadong Medicine22 open or runningphase 1since Jul 18, 2025Jul 18, 2025Jan 31, 2027phase 1 · NCT07638891

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 18, 2025First study: phase 1 study in Solid TumorFirst studyNCT07098052 · 60 planned · China
  2. Jun 5, 2026Phase 1 study in Squamous Non-small Cell Lung Cancer(NSCLC)NCT07638891 · 150 planned · China

Ahead

  1. Jan 31, 2027Primary completion: phase 1 study in Squamous Non-small Cell Lung Cancer(NSCLC)NCT07638891

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07638891Squamous Non-small Cell Lung Cancer(NSCLC) · China1RecruitingJan 31, 2027150
NCT07098052Solid Tumor · China1RecruitingSep 30, 202660

How it is read

Names in the registry

  • “HDM2020 (FGFR2b-ADC)”, 1 entry
  • “HDM2020”, 1 entry

Codes read as this program: HDM2020.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.